Skip to main content
  • Connect with Us
Home

Search form

  • Home
    • About Us
  • Membership
  • GCIG Roster
  • Chicago 2020
  • Past Meetings
    • Athens 2019
    • Chicago 2019
    • Munich 2018
    • Chicago 2018
    • Vienna 2017
    • Chicago 2017
    • Lisbon 2016
    • Chicago 2016
    • Japan 2015
    • Chicago 2015
    • Melbourne 2014
    • Chicago 2014
    • London 2013
    • Chicago 2013
    • Leiden 2012
    • Chicago 2012
    • Milan 2011
  • Calendar
    • Event Listing
  • CA 125 Response Definition
  • GCIG Clinical Trials
  • Bibliography
  • CCRN Committee
    • GCIG CCRN Education Symposium, Johannesburg, January 2019
    • GCIG CCRN Education Symposium, Bucharest, January 2018
    • GCIG CCRN Education Symposium, Mexico, January 2017
    • GCIG CCRN Education Symposium, Bangkok, January 2016
  • Clinical Q&A
  • Educational Symposia
  • GCIG Pathology
  • Advocacy
  • Harmonization
Home /Biblio

Biblio

Found 2 results
Author Keyword Title Type [ Year(Asc)]
Filters: Author is Kim, Byoung-Gie  [Clear All Filters]
2014
A. du Bois, Floquet, A., Kim, J. - W., Rau, J., Del Campo, J. M., Friedlander, M. Leonard, Pignata, S., Fujiwara, K., Vergote, I. B., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M. - A., Kim, J. - H., Kurzeder, C., Lesoin, A., Vasey, P. A., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B. - G., Herzog, T. J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R. J., and Harter, P., “Incorporation of pazopanib in maintenance therapy of ovarian cancer.”, J Clin Oncol, vol. 32, no. 30, p. 3382, 2014.
2011
J. A. Ledermann, Marth, C., Carey, M. S., Birrer, M. J., Bowtell, D. D. L., Kaye, S. B., McNeish, I., Oza, A. M., Scambia, G., Rustin, G. J. S., Stehman, F. B., Gershenson, D., Thomas, G., Berns, E. M. J. J., Casado, A., Ottevanger, N., Hilpert, F., Kim, B. - G., Okamoto, A., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., “Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 763-70, 2011.